https://doi.org/10.4081/hmr.v1i9.319

Low molecular weight heparin and survival in cancer

Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005
Published: June 3, 2009
Abstract Views: 160
PDF: 166
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

AK Kakkar
support@pagepress.org
More recent clinical trials have evaluated the potential benefits of low molecular weight heparin therapy in prolonging survival in patients with solid tumour malignancy. The Fragmin Advance Malignancy Outcome Study (FAMOUS) randomised 385 patients to receive the low molecular weight heparin dalteparin sodium (5000 units once daily) or normal saline placebo injections for up to 1 year. Patients in this trial had advanced disease (locally advanced or disseminated). The primary endpoint of this study was mortality one year after randomisation. 46% of dalteparin patients compared to 41% of placebo group patients were alive at 1 year (p=n.s). In a post-hoc sub-group analysis of good prognosis patients (n=102) dalteparin administration was associated with an increase of median survival from 24 months in the placebo group to 43 months in the dalteparin group.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Kakkar, A. (2009). Low molecular weight heparin and survival in cancer. Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.319
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).